Navigation Links
NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
Date:5/16/2012

ver a 24-hour period compared to placebo with a fast onset of action at first dose, as well as improving exercise endurance. It was submitted for regulatory approval in Europe in Q3 2011 and Japan in Q4 2011, and expected US filing is in the beginning of 2014. NVA237 was licensed to Novartis in April 2005 by Sosei and our co-development partner Vectura.

Indacaterol (Onbrez® Breezhaler®) is Novartis' once daily long acting beta2-agonist (LABA). Novartis received European regulatory approval for 150 mcg and 300 mcg once-daily doses, under the brand name Onbrez® Breezhaler® in November 2009. In July 2011, Novartis announced approval of the 75 mcg once-daily dose in the US under the brand name Arcapta™ Neohaler™, and of the 150 mcg once-daily dose in Japan under the brand name Onbrez® Inhalation Capsules.

QVA149 (indacaterol 110 mcg/glycopyrronium bromide 50 mcg) is an investigational inhaled, once-daily, fixed dose combination of the long acting beta2-agonist (LABA) indacaterol, and the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide (NVA237). The first four QVA149 Phase III studies in the treatment of COPD all met their primary endpoints. The results of the SHINE, BRIGHT, ENLIGHTEN and ILLUMINATE studies, which are key components of the IGNITE program, demonstrate the potential of QVA149 in the treatment of COPD. Filing for QVA149 in Europe is expected in Q4 2012.

About COPD

COPD is a progressive disease associated mainly with tobacco smoking, air pollution or occupational exposure, which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness. It affects an estimated 210 million people worldwide[1]and is predicted to be the third leading cause of death by 2020[2]. Although COPD is often thought of as a disea
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress
2. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
3. Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
4. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
5. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
6. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
7. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
9. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
10. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
(Date:7/10/2014)... Quebec , July 10, 2014  Valeant Pharmaceuticals ... VRX) today announced it has completed the sale to ... and Dysport owned or held by Valeant for $1.4 ... with Nestle S.A, which recently completed its acquisition of ... the divestiture of our products to a company that ...
(Date:7/10/2014)...   LabStyle Innovations Corp . (OTCQB:DRIO), developer of ... appointment of Professor Richard B. Stone ... Directors. Prof. Stone brings over forty-five ... as an entrepreneur, venture capitalist public, company officer ... He currently serves on the board of directors ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
(Date:7/13/2014)... The North American water storage systems market is estimated ... by 2018, at a CAGR of 21.0%, from 2013 to ... rapid pace in North America. The U.S. is experiencing high ... wastewater storage and collection, and the increased spending on modernization ... a healthy rate in Canada, and is rising at a ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Fuel additives ... as gasoline, diesel, jet fuel, kerosene, and so on, ... also responsible for reducing the corrosion effects caused by ... when added to any fuel, provide economies of scale ... these escalate the overall cost of the fuel products. ...
(Date:7/13/2014)... Serena Gordon HealthDay Reporter ... type of sensor for people with diabetes is being developed ... of blood, researchers report. Scientists at Brown University in ... artificial saliva. It uses light, metal and a special enzyme ... knows that diabetics have to prick their fingers to draw ...
(Date:7/13/2014)... 13, 2014 Recently, 2014QuinceaneraDresses.com, the ... unveiled its new range of gorgeous Quinceanera ... the demand for elegant Quinceanera outfits is huge. ... items. All the company’s newly released dresses are ... are all elegant and vivid. , It ...
(Date:7/13/2014)... Epidemiologists forecast an increase in the ... 8,062 diagnosed incident cases in 2013 to 11,568 diagnosed ... (AGR) of 4.35%, during the forecast period. In 2023, ... incident cases of aGVHD in the 6MM, with 4,989 ... number of diagnosed incident cases of aGVHD, with 704 ...
Breaking Medicine News(10 mins):Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4
... Gribbin of Clarksburg, president and CEO of CentraState Healthcare ... the board of the New Jersey Hospital Association (NJHA), ... well as the appointment of new board members, was ... Regency Princeton. "Here in our state, the enormous problems ...
... A French study reported in the 12th January issue ... a strong correlation between blood pressure and outdoor temperature ... result, the investigators advise that, during periods of extreme ... "could contribute to reducing the consequences of blood pressure ...
... at National Jewish Health and the University of Colorado Denver ... among patients with acute lung injury. Acute lung injury (ALI) ... low oxygen levels in the blood, and fluid in the ... intensive care units, afflicting almost 200,000 people in the United ...
... As the health insurance market increasingly becomes consumer-driven, BlueCross ... shopping for insurance with face-to-face assistance at the company,s ... 23 in Mount Pleasant, S.C.Located at 615 Johnnie Dodds ... Shopping Center, the 1,800 square foot SC BlueStore(SM) ...
... BEAVERTON, Ore., Jan. 16 Includesdental.com announces ... for dentists, hygienists and other oral health ... to search for product reviews, clinical research, ... across thousands of sites."With Includesdental.com, dentists can ...
... severity among female patients., , , FRIDAY, Jan. 16 (HealthDay ... often and more severely than men, new research suggests. ... from around the world who had RA, about 79 ... had poorer outcomes in key measures such as symptoms ...
Cached Medicine News:Health News:Hospital Association Names New Chairman, Appoints Board Officers and New Members 2Health News:Seasonal variation in blood pressure 2Health News:Gene associated with reduced mortality from acute lung injury 2Health News:S.C. BlueCross to Open Its First Health Insurance Retail Store 2Health News:Includesdental.com Announces Search Engine for Dentists, Hygienists and Oral Health Industry 2Health News:Rheumatoid Arthritis Hits Women Harder 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: